Four-Step Preclinical Strategy to Tackle Cancer Drug Resistance

Cancer drug resistance remains a significant hurdle in oncology, representing one of the greatest challenges in the development of effective cancer therapeutics. As resistance mechanisms evolve, they contribute to treatment failure and cancer-related mortality, underscoring the need for innovative solutions. The complexity of resistance — whether intrinsic or acquired — can be daunting and requires nuanced approaches for effective targeting and model development.

In this webinar, the expert speaker will explore the evolving landscape of drug resistance and focus on innovative preclinical tools and strategies that can accelerate therapeutic discovery and provide actionable insights into overcoming resistance. She will also demonstrate how an integrated approach to early drug discovery can streamline the identification and development of new therapeutic strategies to counteract resistance.

The speaker will also outline a robust four-step approach that can assist in identifying the most effective preclinical models to tackle both intrinsic and acquired resistance. This includes leveraging cutting-edge in vitro and in vivo models coupled with genetic engineering, imaging and multiomics advanced technologies designed to recapitulate resistance phenotypes and help identify resistance mechanisms early in the drug discovery process.

In this webinar, the attendees will gain insights into specific models that have been developed to study resistance to targeted therapies and immunotherapeutics. The speaker will explore their key features, challenges and practical applications that can help in understanding how to utilize these models to predict clinical outcomes more effectively.

Register for this webinar today to explore the landscape of cancer drug resistance and learn how innovative preclinical tools and strategies can accelerate the discovery of cancer therapies.

Speaker

Rajendra Kumari, PhD, Executive Director, Scientific Operations, Crown Bioscience

Rajendra Kumari leads the focus of cross-disciplinary integrated solutions for drug discovery and development at Crown Bioscience. She has over 20 years of oncology research experience with a PhD in Molecular Pharmacology.

Prior to joining Crown Bioscience, Rajendra was an Assistant Professor, Division of Preclinical Oncology, at the Medical School, University of Nottingham, where she developed in vitro and in vivo preclinical models, including patient-derived systems and imaging capabilities.

Rajendra also co-founded PRECOS Ltd. in 2010, serving as the COO. Then, following the merger with Crown Bioscience, she was the CSO and General Manager for Crown Bioscience UK. In 2018, Rajendra became the Global Head of Scientific Communications for all platforms at Crown Bioscience, working closely with multiple divisions and global departments to support the commercialization of R&D activity and capabilities. Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications.

Message Presenter